NCT05636306View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

October 5, 2023

Study Completion Date

October 5, 2023

Conditions
First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
Interventions
DRUG

NoNO-42

A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute

DRUG

Placebo

A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.

Trial Locations (1)

H3P 3P1

Altasciences Company Inc., Mount Royal

All Listed Sponsors
lead

NoNO Inc.

INDUSTRY